

Special Issue

Bioengineering and Nanotechnology to Create Advanced Therapeutics for Neurological Disorders and Neurosensory Pathologies

Message from the Guest Editors

Recent advances in the therapeutics of neurological disorders have brought to light the need for modernized delivery systems for controlled, targeted distribution to the site of action. Often in neuropharmacology, the site of interest is physiologically impenetrable due to (1) biological/physiological barriers, (2) abundance of drug efflux transporters hostile to xenobiotics and (3) anatomical restrictions resulting in inadvertent loss of drug, low drug perfusion and poor uptake to tissues. Traditional approaches of pharmaceutical sciences cannot be extrapolated to the delivery of biotherapeutics to treat neurological disorders, thus the need to accelerate research incorporating novel bioengineering and nanotechnology systems. The purpose of this Special Issue is to consolidate and facilitate novel therapeutic approaches in the management of neurological disorders, including but not limited to neurosensory hearing loss, balance disorders and pathologies leading to CNS diseases, as well as inflammatory conditions and oxidative stress leading to neurological pathophysiology.

Guest Editors

Dr. Armin Mooranian

Biotechnology and Drug Development Research Laboratory, Curtin Medical School & Curtin Health Innovation Research Institute, Curtin University, Kent St, Bentley, WA 6102, Australia

Dr. Hani Al-Salami

Biotechnology and Drug Development Research Laboratory, Curtin Medical School & Curtin Health Innovation Research Institute, Curtin University, Kent St, Bentley, WA 6102, Australia

Deadline for manuscript submissions

closed (20 September 2023)



Pharmaceutics

an Open Access Journal
by MDPI

Impact Factor 5.5
CiteScore 10.0
Indexed in PubMed



mdpi.com/si/93746

Pharmaceutics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceutics@mdpi.com

[mdpi.com/journal/
pharmaceutics](https://mdpi.com/journal/pharmaceutics)





Pharmaceutics

an Open Access Journal
by MDPI

Impact Factor 5.5
CiteScore 10.0
Indexed in PubMed



[mdpi.com/journal/
pharmaceutics](https://mdpi.com/journal/pharmaceutics)



About the Journal

Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceuticals and biopharmaceuticals. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

Editor-in-Chief

Prof. Dr. Patrick J. Sinko
Department of Pharmaceutics, Ernest Mario School of Pharmacy,
Rutgers University, Piscataway, NJ 08854, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1
(Pharmaceutical Science)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 14.9 days after submission; acceptance to publication is undertaken in 3.3 days (median values for papers published in this journal in the first half of 2025).